Tumour targetable and microenvironment-responsive nanoparticles simultaneously disrupt the PD-1/PD-L1 pathway and MAPK/ERK/JNK pathway for efficient treatment of colorectal cancer

References

• Araghi M, Soerjomataram I, Jenkins M, et al. Global trends in colorectal cancer mortality: projections to the year 2035. Int J Cancer. 2019;144(12):2992–3000.
   PubMed Web of Science ®Google Scholar
• Levin TR, Corley DA, Jensen CD, et al. Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. Gastroenterology. 2018;155(5):1383–1391.
   PubMed Web of Science ®Google Scholar
• Nishimoto H. Colorectal cancer epidemiology in Japan: mortality, incidence, survival. Nihon Rinsho. 2016;74(11):1786–1789.
   PubMedGoogle Scholar
• Jideh B, Bourke MJ. Colorectal cancer screening reduces incidence, mortality and morbidity. Med J Aust. 2018;208(11):483–484.
   PubMed Web of Science ®Google Scholar
• Navarro M, Nicolas A, Ferrandez A, et al. Colorectal cancer population screening programs worldwide in 2016: an update. World J Gastroenterol. 2017;23(20):3632–3642.
   PubMed Web of Science ®Google Scholar
• Versace VL, Forsyth AD, Vaughan R, et al. Evidence of elevated colorectal cancer and adenoma rates for regional National Bowel Cancer Screening Program participants. Aust J Rural Health. 2018;26(1):63–64.
   PubMed Web of Science ®Google Scholar
• Mauldin IS, Tung KS, Lorenz UM. The tyrosine phosphatase SHP-1 dampens murine Th17 development. Blood. 2012;119(19):4419–4429.
   PubMed Web of Science ®Google Scholar
• Dempke WCM, Uciechowski P, Fenchel K, et al. Targeting SHP-1, 2 and SHIP pathways: a novel strategy for cancer treatment? Oncology. 2018;95(5):257–269.
   PubMed Web of Science ®Google Scholar
• Raymond AA, Javary J, Breig O, et al. Reptin regulates insulin-stimulated Akt phosphorylation in hepatocellular carcinoma via the regulation of SHP-1/PTPN6. Cell Biochem Funct. 2017;35(6):289–295.
   PubMed Web of Science ®Google Scholar
• Tao T, Yang X, Zheng J, et al. PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation. Oncogene. 2017;36(44):6119–6131.
   PubMed Web of Science ®Google Scholar
• Youssef G, Gillett C, Rampling D, et al. The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma. Hum Pathol. 2019;86:182–192.
   PubMed Web of Science ®Google Scholar
• Sarmiento N, Sánchez-Bernal C, Ayra M, et al. Changes in the expression and dynamics of SHP-1 and SHP-2 during cerulein-induced acute pancreatitis in rats. Biochim Biophys Acta. 2008;1782(4):271–279.
   PubMed Web of Science ®Google Scholar
• Rego D, Kumar A, Nilchi L, et al. IL-6 production is positively regulated by two distinct Src homology domain 2-containing tyrosine phosphatase-1 (SHP-1)-dependent CCAAT/enhancer-binding protein β and NF-κB pathways and an SHP-1-independent NF-κB pathway in lipopolysaccharide-stimulated bone marrow-derived macrophages. J Immunol. 2011;186(9):5443–5456.
   PubMed Web of Science ®Google Scholar
• Wen LZ, Ding K, Wang ZR, et al. SHP-1 acts as a tumor suppressor in hepatocarcinogenesis and HCC progression. Cancer Res. 2018;78(16):4680–4691.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang S, Liu X, et al. Aberrant promoter 2 methylation-mediated downregulation of protein tyrosine phosphatase, non-receptor type 6, is associated with progression of esophageal squamous cell carcinoma. Mol Med Rep. 2019;19:3273–3282.
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.
   PubMed Web of Science ®Google Scholar
• Vari F, Arpon D, Keane C, et al. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 2018;131(16):1809–1819.
   PubMed Web of Science ®Google Scholar
• Wu X, Gu Z, Chen Y, et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:661–674.
   PubMed Web of Science ®Google Scholar
• Song MK, Park BB, Uhm J. Understanding immune evasion and therapeutic targeting associated with PD-1/PD-L1 pathway in diffuse large B-cell lymphoma. Int J Mol Sci. 2019;20(6):1326.
   Web of Science ®Google Scholar
• Concha-Benavente F, Kansy B, Moskovitz J, et al. PD-L1 mediates dysfunction in activated PD-1+ NK cells in head and neck cancer patients. Cancer Immunol Res. 2018;6(12):1548–1560.
   PubMed Web of Science ®Google Scholar
• Shergold AL, Millar R, Nibbs RJB. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacol Res. 2019;145:104258.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–2391.
   PubMed Web of Science ®Google Scholar
• Lo Russo G, Moro M, Sommariva M, et al. Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade. Clin Cancer Res. 2019;25(3):989–999.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301.
   PubMed Web of Science ®Google Scholar
• Tapia Rico G, Price TJ. Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. Expert Opin Biol Ther. 2018;18(4):449–457.
   PubMed Web of Science ®Google Scholar
• Cyprian FS, Akhtar S, Gatalica Z, et al. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: a new clinical paradigm in the treatment of triple-negative breast cancer. Bosn J Basic Med Sci. 2019;19:227–233.
   PubMed Web of Science ®Google Scholar
• Penafuerte C, Perez-Quintero LA, Vinette V, et al. Mining the complex family of protein tyrosine phosphatases for checkpoint regulators in immunity. Curr Top Microbiol Immunol. 2017;410:191–214.
   PubMed Web of Science ®Google Scholar
• Watson HA, Dolton G, Ohme J, et al. Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1. Immunol Cell Biol. 2016;94(8):802–808.
   PubMed Web of Science ®Google Scholar
• Olson ES, Jiang T, Aguilera TA, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A. 2010;107(9):4311–4316.
   PubMed Web of Science ®Google Scholar
• Feng X, Jiang D, Kang T, et al. Tumor-homing and penetrating peptide-functionalized photosensitizer-conjugated PEG-PLA nanoparticles for chemo-photodynamic combination therapy of drug-resistant cancer. ACS Appl Mater Interfaces. 2016;8(28):17817–17832.
   PubMed Web of Science ®Google Scholar
• Gu G, Xia H, Hu Q, et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials. 2013;34:196–208.
   PubMed Web of Science ®Google Scholar
• André P, Denis C, Soulas C, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK Cells. Cell. 2018;175(7):1731–1743.
   PubMed Web of Science ®Google Scholar
• Luo L, Zhu C, Yin H, et al. Laser immunotherapy in combination with perdurable PD-1 blocking for the treatment of metastatic tumors. ACS Nano. 2018;12(8):7647–7662.
   PubMed Web of Science ®Google Scholar
• Wei F, Zhang T, Deng SC, et al. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. Cancer Lett. 2019;450:1–13.
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5(4):496–504.
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505–515.
   PubMed Web of Science ®Google Scholar
• Williford JM, Wu J, Ren Y, et al. Recent advances in nanoparticle-mediated siRNA delivery. Annu Rev Biomed Eng. 2014;16:347–370.
   PubMed Web of Science ®Google Scholar
• Qian Y, Zha Y, Feng B, et al. PEGylated poly(2-(dimethylamino) ethyl methacrylate)/DNA polyplex micelles decorated with phage-displayed TGN peptide for brain-targeted gene delivery. Biomaterials. 2013;34(8):2117–2129.
   PubMed Web of Science ®Google Scholar
• Huang H. Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances. Sensors (Basel). 2018;18(10):3249.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.
   PubMed Web of Science ®Google Scholar
• Kim CW, Oh ET, Kim JM, et al. Hypoxia-induced microRNA-590-5p promotes colorectal cancer progression by modulating matrix metalloproteinase activity. Cancer Lett. 2018;416:31–41.
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Zhang S, et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep. 2013;3:2534.
   PubMed Web of Science ®Google Scholar
• García-Hernández V, Sarmiento N, Sánchez-Bernal C, et al. Modulation in the expression of SHP-1, SHP-2 and PTP1B due to the inhibition of MAPKs, cAMP and neutrophils early on in the development of cerulein-induced acute pancreatitis in rats. Biochim Biophys Acta. 2014;1842(2):192–201.
   PubMed Web of Science ®Google Scholar
• Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71–79.
   PubMed Web of Science ®Google Scholar
• Ernsting MJ, Murakami M, Roy A, et al. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release. 2013;172(3):782–794.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074.
   PubMed Web of Science ®Google Scholar
• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.
   PubMed Web of Science ®Google Scholar
• Nouri Rouzbahani F, Shirkhoda M, Memari F, et al. Immunotherapy a new hope for cancer treatment: a review. Pak J Biol Sci. 2018;21(3):135–150.
   PubMedGoogle Scholar
• Calles A, Liao X, Sholl LM, et al. Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer. J Thorac Oncol. 2015;10(12):1726–1735.
   PubMed Web of Science ®Google Scholar
• Tan S, Liu K, Chai Y, et al. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2018;9(1):135–139.
   PubMed Web of Science ®Google Scholar